# Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.

Study · id `cardio:ct-nct02050529` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02050529](<https://clinicaltrials.gov/study/NCT02050529>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02050529

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 190 participants.

## Technical summary

Registry record NCT02050529. Randomized; single masking; primary purpose treatment. Start 2012-10 (actual); primary completion 2014-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 190 participants (enrolled count; ClinicalTrials.gov record NCT02050529, source copy `cardio:ctgov-nct02050529-2018-10-26`, retrieved 2026-10-26)
- Started: 2012-10 (actual) (ClinicalTrials.gov record NCT02050529, source copy `cardio:ctgov-nct02050529-2018-10-26`, retrieved 2026-10-26)
- Primary completion: 2014-09 (actual) (ClinicalTrials.gov record NCT02050529, source copy `cardio:ctgov-nct02050529-2018-10-26`, retrieved 2026-10-26)
- Completion: 2015-03 (actual) (ClinicalTrials.gov record NCT02050529, source copy `cardio:ctgov-nct02050529-2018-10-26`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT02050529, source copy `cardio:ctgov-nct02050529-2018-10-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02050529-2018-10-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.
- Condition: Hypertension, Pregnancy Induced
- Condition: Hydralazine Adverse Reaction
- Condition: Pre-eclampsia
- Condition: Pre-eclampsia Superimposed Pre-existing Hypertension
- Intervention (Drug): Labetalol
- Intervention (Drug): Hydralazine
- Lead sponsor: Dow University of Health Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Dow University of Health Sciences (`cardio:org-dow-university-of-health-sciences`)

## Provenance

Content hash: 68b3880c8b231caf59f295b04875aae940f0f2820b15a9271629eec81b769421
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
